Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Stock Information for Galecto Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galecto Inc.

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Galecto Announces Acquisition of Damora Therapeutics
Galecto Reports Third Quarter 2025 Operating and Financial Results
Galecto to Highlight GB3226 Program at ASH 2025
Galecto Reports Second Quarter 2025 Operating and Financial Results
Galecto Reports First Quarter 2025 Operating and Financial Results
Galecto Reports Full-Year 2024 Financial Results
Galecto to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.